Sulfentanil
PreclinicalSmall molecule
Sulfentanil is one of 25 small molecule programs targeting Strabismus. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Strabismus
#DrugCompanyPhaseTrials
1Botox
RRevance Therapeutics, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Decadron
AAspen Global Incorporated
Approved
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Aloxi
AAvyxa
Approved
GSK1358820
GSKPhase 3
Botulinum Toxin a
GSKPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Tylenol
MMetroHealth Medical Center
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulfentanil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details